Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Immunoclin Corp | Financial_Report.xls |
| 10-Q - MAY 31, 2012 FORM 10Q - Immunoclin Corp | f10q053112_10q.htm |
| EX-31.2 - EXHIBIT 31.2 CERTIFICATION RULE 13A-14 - Immunoclin Corp | f10q053112_ex31z2.htm |
| EX-31.1 - EXHIBIT 31.1 CERTIFICATION RULE 13A-14 - Immunoclin Corp | f10q053112_ex31z1.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Pharma Investing News, Inc., (the “Company”) on Form 10-Q for the period ending May 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Lawrence, Chief Executive Officer and Chief Financial Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Robert Lawrence
By: Robert Lawrence
Chief Executive Officer and Chief Financial Officer
Dated: July 16, 2012
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.